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Abstract
Background: Urodele amphibians like the axolotl are unique among vertebrates in their ability to
regenerate and their resistance to develop cancers. It is unknown whether these traits are linked
at the molecular level.
Results:  Blocking p53 signaling in axolotls using the p53 inhibitor, pifithrin-α, inhibited limb
regeneration and the expression of p53 target genes such as Mdm2 and Gadd45, suggesting a link
between tumor suppression and regeneration. To understand this relationship we cloned the p53
gene from axolotl. When comparing its sequence with p53 from other organisms, and more
specifically human we observed multiple amino acids changes found in human tumors. Phylogenetic
analysis of p53 protein sequences from various species is in general agreement with standard
vertebrate phylogeny; however, both mice-like rodents and teleost fishes are fast evolving. This
leads to long branch attraction resulting in an artefactual basal emergence of these groups in the
phylogenetic tree. It is tempting to assume a correlation between certain life style traits (e.g.
lifespan) and the evolutionary rate of the corresponding p53 sequences. Functional assays of the
axolotl p53 in human or axolotl cells using p53 promoter reporters demonstrated a temperature
sensitivity (ts), which was further confirmed by performing colony assays at 37°C. In addition,
axolotl p53 was capable of efficient transactivation at the Hmd2 promoter but has moderate
activity at the p21 promoter. Endogenous axolotl p53 was activated following UV irradiation (100
j/m2) or treatment with an alkylating agent as measured using serine 15 phosphorylation and the
expression of the endogenous p53 target Gadd45.
Conclusion: Urodele p53 may play a role in regeneration and has evolved to contain multiple
amino acid changes predicted to render the human protein defective in tumor suppression. Some
of these mutations were probably selected to maintain p53 activity at low temperature. However,
other significant changes in the axolotl proteins may play more subtle roles on p53 functions,
including DNA binding and promoter specificity and could represent useful adaptations to ensure
p53 activity and tumor suppression in animals able to regenerate or subject to large variations in
oxygen levels or temperature.
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Background
Inactivation of p53 by mutations or viral oncogenes is the
most frequent alteration found in human cancers [1]. P53
counteracts the process of neoplastic transformation by
preventing the proliferation of cells with genomic abnor-
malities [1]. Multiple stress conditions activate p53
including DNA damage, hypoxia, redox stress, ribonucle-
otide imbalance, cell adhesion and oncogenes [2-5]. In
response to these signals, p53 undergoes a variety of post-
translational modifications, such as phosphorylation,
acetylation and sumolation, which modulate its stability
and activity [5]. The effects of p53 are mediated through
the induction of a variety of genes that have not yet been
fully characterized. These genes induce transient cell cycle
arrest, permanent cell cycle arrest program (senescence) or
a cell death program (apoptosis) [1,6].
Most of the research trying to resolve the function of p53
has been accomplished on transformed cells. However,
cell culture experiments represent only a limited perspec-
tive of the non-autonomous function of p53 as it occurs
in whole organisms. Hence, the function of p53 beyond
that observed in isolated cells remains largely a black box.
Needless to say, that the actual role of p53 in vivo is not
well understood. For these reasons researchers have
turned to the mouse as an in vivo model system to study
p53 functions [7]. The mouse system circumvents many
of the problems associated with the use of cultured cells to
study p53, but fails to model the human condition in a
number of important issues. One critical difference is the
short life span exhibited by laboratory mice. Longevity in
humans imposes a high selective pressure to develop and
refine tumor suppression pathways that might be better
studied in other long living animal models. In addition,
p53 null mice are surprisingly normal [8]. The longevity
factor is also of importance considering the ability of p53
to promote aging in mice even while increasing cancer
protection [9]. For these reasons, knowledge of the p53
pathway in other animal models may contribute critical
insights into its biological functions.
So far, p53 has been characterized in several mammalian
species where its biology follows more or less what is
known in mice and humans [10]. However, selective pres-
sures associated to certain life styles may modify the prop-
erties of p53 and its signaling pathway. For example, the
Israeli mole rat (Spalax) who lives in hypoxic conditions
does not activate p53 in response to hypoxia [11,12]. In
addition, ground squirrels have lower levels of p53 in
their nucleus during hibernation in comparison with ani-
mals during the hot summer season [13]. The discovery of
p53 in model organisms such as Drosophila and C. elegans
revealed that p53 evolved in connection with the regula-
tion of apoptotic pathways in response to DNA damage
[14,15]. Since these animals do not develop tumors, the
p53 tumor suppressor functions probably evolved later in
evolution. Unfortunately, little is known about p53 biol-
ogy in non-mammalian vertebrates, where tumor sup-
pressor functions may play an important role. P53 has
been characterized in zebrafish where its biology and
tumor suppressor functions seem to be similar to mam-
mals [16]. In contrast, a recent study in rainbow trout cells
seems to indicate that p53 is not up-regulated following
exposure to chemotherapeutic drugs [17]. Altogether,
these studies reveal a surprising adaptive capability of the
p53 system to different life styles and suggest that more
interesting variations are still to be found in nature.
In the present study, we used the Mexican salamander,
axolotl (Ambystoma mexicanum), which is a diploid
urodele amphibian with: a remarkable longevity (up to 25
years in captivity) [18]; extensive regenerative capacities
that have been known for centuries [19-22]; and resist-
ance to tumor induction [23,24]. Urodele amphibians
have been used for tissue regeneration and cancer resist-
ance studies for which many authors have established
links between the ability to regenerate and the resistance
to cancer observed in these animals [23-28]. Since p53 is
a tumor suppressor that can influence the rate of aging
and modulate regeneration in both mammals and Dro-
sophila imaginal discs [9,29,30], we reasoned that a long
living animal such as the axolotl may teach us lessons on
how the p53 system is properly modulated to ensure a
long life span, tissue regenerative capacity and efficient
tumor suppression. Here, we show that p53 signaling is
required for limb regeneration, by using a specific phar-
macological inhibitor that has been shown to block p53
signaling in both mammals and zebrafish [31,32] and we
also present the cloning and initial characterization of
p53 in axolotls. We discuss the unique properties of the
axolotl p53 sequence compared to both short living
(mice, flies) and long living species (moles, humans). By
understanding the evolutionary changes that have
occurred in genes such as p53, we may be able to under-
stand better why mutations in this gene cause neoplasia
[16] and how it can mediate tissue regeneration [33].
Results
Requirement of p53 signaling for limb regeneration
We have used the small molecule inhibitor pifithrin alpha
(pifithrin-α) to block the action of p53 during the process
of limb regeneration in axolotls [31,32,34-36]. Pifithrin-α
was administered at the time of amputation, directly in
the water that axolotls are kept in, at a final concentration
of 5 μM (a concentration demonstrated to be specific for
p53 inhibition [35]). Control animals were administered
a volume of DMSO corresponding to the volume for pifit-
hrin. Limb regeneration was monitored at regular inter-
vals until the control treated limbs had completely
regenerated (25 days). The pifithrin-α treated animals dis-BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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played a significant inhibition in the regenerative process
as seen in figure 1. Animals treated with pifithrin-α dis-
played normal growth compared to control treated size
matched animals which indicates that the effects of pifit-
hrin-α were not due to general toxicity (table-1).
Axolotl p53 protein, sequence comparison and phylogeny
We cloned the axolotl full-length p53 cDNA by a combi-
nation of PCR and cDNA library screening approaches.
The axolotl p53 protein (GENBANK accession number
DQ848588) has an open reading frame of 387 amino
acids with significant sequence similarity to the human
p53 protein (Figure 2A–B). Functional domains of the
axolotl p53 protein that correspond to the human protein
sequence can be readily identified, namely the N-terminal
domain (transactivation domain (residues 1–53 of the
human protein), proline rich domain [37] (residues 60–
92), the DNA binding domain (residues 80–301), the
tetramerization domain (residues 316–347), and the C-
terminal regulatory domain (residues 352–388) [38].
The critical residues for protein stability and protein-pro-
tein interactions in the N-terminus corresponding to ser-
ine 15 and serine 20 are conserved. Since these residues
are the target of p53 regulation by phosphorylation in
response to DNA damage, they suggest that axolotl p53 is
also activated by DNA damage inducing stress. The resi-
dues F19, W23 and L26, important for the binding of
Mdm2, are also present [39]. Furthermore, regions I of the
transactivation domain as well as regions II-V of the DNA
binding domain (II-IV-V bind to SV40 T Antigen) can be
easily distinguished [40] (Figure 2B). Several residues
present in the tetramerization domain of p53 proteins
such as: E326, G334, E339, M340, N345, L348, and L350
are conserved as well (Figure 2B) [41]. Finally, it is possi-
ble to observe the NLS (Nuclear Localization Signal, resi-
dues 296–314) and the NES (Nuclear Export Signal,
residues 332–343) (Figure 2B) [42].
We compared the sequence of the axolotl protein with the
database of p53 mutants [43]. We found 38 amino acid
changes in the axolotl protein that corresponded to muta-
tions present in human cancers or affect protein stability
or modify sites of importance for post-translational mod-
ifications (table-2 which also contains scorecons [44]).
They include the sites frequently mutated in human can-
cers: T155, V157 and R283. Noticeable the changes T155A
and V157L are common to human p53 mutant proteins
and axolotl p53. On the other hand, the residue R283 was
found substituted for Lysine in axolotl, a change that abol-
ished DNA binding for the human protein [45].
We also compared the sequence of axolotl p53 with that
of Spalax, the newt, Xenopus and the human. We found
that R174 present in human is substituted by a lysine in
Spalax, newt, Xenopus  and axolotl. K174 in Spalax  is
believed to be linked to a reduced ability of p53 to induce
apoptosis [11]. In human tumors, R174 has been found
mutated into several different amino acids including
lysine [46,47]. In vivo analysis, in a yeast model of p53
transactivation performed at 30°C, showed that p53K174
was able to transactivate several p53 promoter-reporters
similar to wild type p53 [48].
Given that R174K mutation was not a unique sequence
feature of axolotl p53, we conducted a sequence align-
ment of the p53 from several vertebrates spanning mam-
mals to fish (human, mouse, rat, Spalax, chicken, axolotl,
Xenopus, barbel & zebrafish) to identify the changes in
table-2 that are unique to the axolotl p53. We found that
the changes T155A, D186N, L188D, D207M & D228G
represented positions for which a non-conservative
change was present only in the axolotl (additional file 1).
Notably the changes A189S, D208N & G262E were
unique to the axolotl.
We used our new axolotl sequence and many already pub-
lished p53 protein sequences from vertebrates to con-
struct a maximum likelihood based phylogenetic tree (35
sequences and 280 unambiguously aligned amino acid
positions). The phylogenetic tree of p53 is in general
agreement with the known vertebrate phylogeny (Figure
3). Intriguingly both rodents and fishes were clearly
divided into two groups in the p53 phylogeny.
The taxonomic distribution is strongly biased in favor of
mammalian (22 sequences) and ray-finned fish (eight
sequences). The four Neoteleost fish are evolving very rap-
idly resulting in artefactual basal position. This long
branch attraction artefact is induced by the distantly
Effect of pifithrin-α on limb regeneration Figure 1
Effect of pifithrin-α on limb regeneration. (A & E) Con-
trols treated daily with DMSO. (B-D & F-G) Pifithrin-α 
treated animals (5 μM pifithrin-α, added freshly diluted eve-
ryday). Limbs in panels A-D were amputated distally in the 
middle of the zeugopod and limbs in panels E-G were ampu-
tated proximally through the middle of the stylopod (see 
dotted lines in panels A & E for amputation levels).BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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related and rather fast evolving tetrapods. But also in
other parts of the tree there are clear differences in the evo-
lutionary rates (although less striking) among the differ-
ent groups and also between species of the same group,
indicated by the branch length of the rooted tree. There is
a pronounced acceleration observed for the mice-like
rodents (Muroidea), with a clear exception represented by
the sequence of the already mentioned mole rat Spalax.
There also seems to be a rough inverse correlation
between the evolutionary rates inferred for the p53
Comparison between Human and axolotl p53 important domains, regions and residues Figure 2
Comparison between Human and axolotl p53 important domains, regions and residues. (A) Schematic structure 
of p53 protein (adapted from Appella, 2001 [71]): TA, Transactivation Domain; DBD, DNA Binding Domain; NLS, Nuclear 
Localisation Signal; TET, tetramerisation domain; REG, Regulatory domain; Regions I-V, highly conserved regions. Lysine (K), 
serine (S) and threonine (T) residues implicated in post-translational modifications are indicated. The protein domains depicted 
in the diagrams are not to scale. (B) Sequences alignment of human and axolotl p53 proteins. The conserved regions I to V are 
highlighted and many changes between the axolotl and human sequence are identified (arrows). See table-2 for a complete list 
of changes associated with mutations in the human protein.
Table 1: Growth of control and pifithrin-α treated animals during limb regeneration
Animal Treatment Lenght of the pre-
amputated animals
Lenght of the animals 24 
days post-treatment and 
amputation
Growth Ratio (pre-amp/
post-amp)
1 Control DMSO 3.5 cm 4 cm 0.88
2 Control DMSO 3.5 cm 3.9 cm 0.9
3 Control DMSO 3.0 cm 3.5 cm 0.86
4 Pifithrin-α 5 μM 3.0 cm 3.5 cm 0.86
5 Pifithrin-α 5 μM 3.2 cm 3.7 cm 0.86
6 Pifithrin-α 5 μM 3.0 cm 3.4 cm 0.88
no significant difference in growth observed between control and pifithrin treated animals (p > 0.05)BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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sequences and the longevity of the species i.e. the faster
the rate the shorter the life span. This is evident for all
mice-like rodents and the guinea pig except Spalax. This is
further supported by the observation that the rather big
and long-living organisms, human and Beluga whale,
have some of the shortest branches within the mammals
(Figure 3). We decided to test the significance of the dif-
ferences in the evolutionary rates especially with respect to
the model organisms, i.e. human, mice, Spalax and axolotl
by applying a Relative Rate Test (RRT) implemented in the
program RRTree [49]. It is well known that the signifi-
cance level is strongly influenced by the distance of the
outgroup, i.e. the closer the outgroup sequence the better
is the sensitivity of the RRT. We decided to compare
within the mammals the Euarchontoglires (here Primates,
Rodents and Lagomorphs) Spalax and Human against the
mouse-related group of rodents (six sequences) with the
chicken as a distant outgroup and the Beluga whale (Lau-
rasiatheria) as a close outgroup. The RRT were giving the
following probabilities (p < 0.05 is significant) for Spalax
versus mouse-related rodents, Beluga whale p = 0.000 and
Chicken p = 0.042 and for human versus mouse-related
rodents, Beluga whale p = 0.002 and Chicken p = 0.135.
Therefore, the observation that Spalax  is more slowly
evolving is significantly supported by the RRT for both
comparisons. However, note the strong dependence of
the p-value on the chosen outgroup. For human, only the
test with the close outgroup is significantly supported. If
we applied the same test to compare the evolutionary rate
of axolotl with the one of Xenopus with the fish and
amniotes as outgroup, the outcome was not significant (p
= 0.310). This is likely due to the fact that the sensitivity
of the test is highly reduced in absence of a close out-
group. The phylogenetic analysis shows that the urodele
p53 sequences are among the slowest evolving ones and
are therefore closer to the ancestral p53 protein of tetrap-
ods. Bayesian inference also yielded similar results (data
not shown) which further substantiate the results of the
phylogenetic analysis presented in figure 3. Unfortu-
nately, because of the lack of p53 sequences in non-mam-
malian vertebrates, there were only good conditions for
the relative rate within mammals and could therefore not
provide reliable information for the evolutionary rate of
the axolotl sequence in comparison to other amphibians.
Thus, we have to exclude any potential correlation with
the longevity of the species until more sequences become
available.
Axolotl p53 can activate the transcription of human p53 target 
promoters in human cells
The amino acid substitutions found in the axolotl p53
protein sequence raises questions about its ability to rec-
ognize and regulate human p53 target genes. To investi-
gate this issue, we used a Dual-Luciferase Reporter assay in
the human p53 deficient cell line H1299. We co-trans-
fected either human or axolotl p53 expressing plasmids
with luciferase reporter constructs fused to the human
Hdm2 and p21 promoters. We performed these assays at
three different temperatures (37°C, 30°C and 25°C) for
two main reasons. First, two changes present in the axolotl
protein have been reported to cause the human protein to
become temperature sensitive (M160T & A189S, Figure
2B and table-2) [50]. Second, the p53 protein from Xeno-
pus laevis was shown to be temperature sensitive, and also
Phylogenetic tree of p53 protein sequences in vertebrates  with bootstrap values Figure 3
Phylogenetic tree of p53 protein sequences in verte-
brates with bootstrap values. Maximum likelihood phylo-
genetic tree based on 35 p53 sequences with 280 amino acid 
positions inferred by the program Treefinder with a 
WAG+Γ8 model. Numbers at internal nodes are corre-
sponding to bootstrap support values, obtained in the analy-
sis of 100 replicates using the same program and model of 
sequence evolution. Due to the dense species sampling 
within the mammals interesting aspects of mammalian evolu-
tion are becoming apparent. There are clear differences in 
the evolutionary rates among the different groups, indicated 
by the branch length of the rooted tree, this is especially true 
for the four Neoteleost fish. There is also an acceleration 
observed for the mouse-like rodents, with a striking excep-
tion represented by the sequence of the mole rat Spalax, 
which is despite the fact of being a rather small rodent even 
more slowly evolving than the related rabbit (Oryctolagus, lag-
omorph). In fact the only sequences among the tetrapods 
(amphibians, reptilian and mammalian) that are more slowly 
evolving than the one from Spalax are from the urodeles 
(axolotl and newts). The primary sequence of salamander 
p53 is more closely related to the ancestral protein of tetra-
pod vertebrates than the p53 proteins of any other of the 
studied groups.BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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contains substitutions at M160, L289 and A353 (table-2)
which rendered the human protein ts [51].
Human p53, as expected, stimulated the Hdm2 promoter,
at 37°C. However, the axolotl protein was relatively inac-
tive at this temperature (Figure 4A). In contrast, at 30°C,
we observed that the human p53 stimulated the Hdm2
promoter by a factor of 24 fold and that the axolotl p53
stimulated a similar increase of 17 fold (Figure 4B). Fur-
ther reduction of the temperature to 25°C shifted the
activity pattern on the Hdm2 promoter. At this tempera-
ture the axolotl protein was twice as active as the human
p53 protein (Figure 4C). Thus, for the Hdm2 reporter, the
human p53 is more active at 37°C and less active at 25°C
while the axolotl p53 activity is less active at 37°C and
more active at 25°C.
On the p21 promoter luciferase reporter, human p53
stimulated 28 folds the activity at 37°C, 10.5 folds at
30°C and 1.6 folds at 25°C (Figure 4D–F). When the
axolotl p53 was assayed, we observed an increase of 1.7
fold at 37°C, an 8.9 folds increase at 30°C and 1.5 fold
increase at 25°C. The peak activity of the axolotl p53 on
this promoter seems to be near 30°C as opposed to 37°C
for the human p53 protein. However, at any given tem-
perature the ability of axolotl p53 to activate the p21 pro-
Table 2: Analysis of the changes in aa of the axolotl p53 protein compared to human p53
Human codon # of mutations 
reported at this 
site
Axolotl codon # of mutations 
identical to the 
axolotl sequence
temperature 
sensitive 
mutations
scorecons aa changes at this 
position S/N/X
S 37 : TCC 4 A : GCA 0 0.35 +/+/+
M 133 : ATG 49 L : CTC 4 1 +/+/+
T 150 : ACA 38 P : CCG 1 0.39 -/+/+
T 155 : ACC 128 A : GCA 12 I, N, P 0.02 -/+/+
V 157: GTC 267 L : CTC 10 0 -/-/+
M 160 : ATG 45 T : ACT 0 I, K, R, T 0 -/+/+
I 162 : ATC 59 V : GTG 7 0 -/+/+
R 174 : AGG 78 K : AAA 12 0 +/+/+
S 185 : AGC 23 P : CCC 0 0.06 -/+/+
D 186 : GAT 23 N : AAT 5 0.01 -/+/+
G 187 : GGT 42 D : GAC 5 0.01 -/+/+
L 188 : CTG 14 D : GAT 0 0 -/+/+
A 189 : GCC 41 S : TCT 1 P, S 0 -/+/-
P 191 : CCT 55 A : GCC 0 0 -/+/-
Q 192 : CAG 112 D : GAT 0 0 -/+/+
L 201 : TTG 33 F : TTC 6 0.03 -/+/-
L 206 : TTG 20 K : AAG 0 F 0.01 -/+/+
D 207 : GAT 23 M : ATG 0 0 -/+/+
D 208 : GAC 49 N : AAT 6 A, V 0 -/-/-
R 209 : AGA 90 S : TCG 1 0.01 +/+/+
F 212 : TTT 47 H : CAT 0 V 0 -/+/+
P 222 : CCG 32 T : ACG 1 0.02 -/+/+
E 224 : GAG 54 Q : CAG 0 0 -/+/+
V 225 : GTT 27 L : CTC 1 0.03 -/-/-
D 228 : GAC 51 G : GGA 6 0.01 -/-/+
I 232 : ATC 67 V : GTG 6 F, M 0 -/+/+
H 233 : CAC 38 L : CTT 2 0 -/+/+
D 259 : GAC 90 T : ACT 0 0.01 -/+/+
G 262 : GGT 46 E : GAG 0 0 -/-/-
N 263 : AAT 24 Q : CAG 0 0.02 -/+/+
N 268 : AAC 25 R : CGC 0 I, T 0.01 -/+/+
S 269 : AGC 46 C : TGC 4 G, I, R 0 -/+/+
R 283 : CGC 126 K : AAG 0 P 0 -/+/-
L 289 : CTC 32 F : TTT 5 P 1 +/+/+
F 338 : TTC 7 Y : TAT 0 S 0.21 -/+/+
E 343 : GAG 7 K : AAG 0 G 0.01 -/+/+
A 353 : GCC 1 M : ATG 0 P 0 +/+/+
S 376 : TCT 2 P : CCT 0 T 0 -/+/+
Bold: aa changes present in axolotl, Spalax (S), Newt (N) and Xenopus (X)
Italic bold: aa changes causing p53 to become temperature sensitiveBMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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Activation of Hdm2 and p21 promoters by human and axolotl p53 in H1299 cells Figure 4
Activation of Hdm2 and p21 promoters by human and axolotl p53 in H1299 cells. (A-C) Dual-luciferase assays in 
H1299 cells with Hdm2 promoter at 37°C, 30°C and 25°C. (D-F) Dual-luciferase assays in H1299 cells with the human p21 
promoter at 37°C, 30°C and 25°C. Luciferase activities stimulated by human or axolotl p53 was significantly different than non-
p53 controls (at least p < 0.05, data not shown). Error bars are ± s.e.m. human and axolotl p53 luciferase transactivation were 
significantly different during the same assay using the Hdm2 promoter (A-C) or the human p21 promoter at 37°C (D) (at least 
p < 0.01). Each assay was performed in triplicate at least 3 separate times. (G) Inhibition of the activation of Hdm2 promoter 
by the combined expression of human and axolotl p53 in H1299 cells. All luciferase activities were significantly different than 
non-p53 controls (at least p < 0.05, data not shown). Error bars are ± s.e.m. human + axolotl and human p53 luciferase trans-
activation were significantly different during the same assay using the Hdm2 promoter at 37°C (p = 0.006). Each assay was per-
formed in triplicate. (H) Growth assays at 37°C on H1299 cells transfected with human or axolotl p53 protein.BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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moter was compromised compared to the Hdm2
promoter. Among the amino acid substitutions of the
axolotl protein that may explain this reduced activity for
the p21 promoter we noticed the change of Ser 37 to Ala
(Table-2). Substitution of Ser 37 for Pro has been detected
in a T lymphoblastoid cell line that is drug resistant. This
mutant has a reduced activity on both the p21 and the p53
promoter [52].
Next we assayed the human and the axolotl p53 together
to activate the Hdm2 promoter luciferase reporter at
37°C. We noted a decrease in the expression of luciferase
when the axolotl protein was transfected together with the
human protein compared with the human p53 alone (Fig-
ure 4G). Hence, the axolotl p53 seems to have a dominant
negative effect on the activity of the human p53 on the
Hdm2 promoter at 37°C, suggesting that they can interact
together.
To have an idea of the functionality of axolotl p53 on a
biological assay, we transfected H1299 cells with con-
structs driving the expression of human p53, axolotl p53
or an empty vector. As expected from the luciferase assays,
axolotl p53 did not reduce colony formation of H1299
cells, while human p53 had a dramatic inhibitory effect in
this assay (Figure 4H). Contrary to the promoter-reporter
assays which were performed 24 h post-transfection, we
could not assay p53 functions for colony formation at
30°C and 25°C in these cells because they did not effi-
ciently attach to the plate at those temperatures for the
required amount of time to select with puromycin (7
days). Together, these results are consistent with the idea
that axolotl p53 is a temperature sensitive protein.
The capacity of the axolotl p53 protein to induce endog-
enous p53 target gene was also tested in the p53 deficient
human H1299 cells. The H1299 cells grown at 30° trans-
fected with the axolotl protein had elevated Hdm2 expres-
sion (Figure 5). We also took advantage of this assay to
confirm the specificity of the pifithrin-α to block the activ-
ity of the axolotl p53 protein (Figure 5).
Axolotl p53 activation in axolotl cells
The axolotl AL1 cell line was used for the subsequent dual-
luciferase reporter assay to measure the activity of human
p53 and axolotl p53. The assays were done at 25°C since
axolotl cells are unable to grow at 37°C or 30°C. The
Hdm2 and p21 reporter genes were used for the assays.
With the Hdm2 promoter, there was a 12.6 fold increase
with human p53 protein and a 26.4 fold increase with the
axolotl p53 protein (Figure 6A). Therefore, the axolotl
p53 protein activity was significantly more efficient than
the human protein at 25°C (p < 0.001) on the Hdm2 pro-
moter in axolotl cells. In contrast, with the p21 promoter,
there was a two-fold increase with the human p53 and 1.9
fold increase with axolotl p53 protein (Figure 6B). Again,
it seems that the DNA binding specificity of the axolotl
protein is different than the human counterpart.
DNA damage and activation of axolotl p53
Since p53 activity has been shown to be modulated by
close to 50 post-translational modifications on the pro-
tein itself, we decided to look at a specific phospho-serine
residue following different treatments. We used the axol-
otl cell line AL1 [53] to assess the effect of ultraviolet irra-
diation on axolotl p53 levels and phosphorylation.
Western blots were performed against phospho p53 ser-
15 on axolotl AL1 cells exposed to UV radiation or the
alkylating agent (N-methyl-n-nitro-n-nitrosoguanidine;
MNNG) which causes DNA breaks [54,55]. The cells
exposed to UV showed an increased phosphorylation of
p53 at serine 15 in comparison to the non-exposed con-
trol cells (Figure 7A). We noticed that anti-p53 antibodies
recognized two bands that followed the same induction
pattern in response to DNA damage. These bands may
represent alternatively spliced p53 isoforms as described
in mammals [56]. The availability of the axolotl ortholog
for Gadd45 allowed us to look at the induction of an
endogenous p53 target gene following UV irradiation of
axolotl cells [57,58]. The capacity of pifithrin-α to block
p53 signaling was also tested. Axolotl cells exposed to UV
irradiation showed an up-regulation of Gadd45 expres-
sion, which was significantly inhibited in the presence of
pifithrin-α (Figure 7B). Treatment with MNNG (10-5M)
also increased p53 phosphorylation at serine 15. The sig-
nal increase for phospho p53 ser-15 was detectable one
hour after drug application and up to 24 hours later (Fig-
ure 7C). On the other hand, an antibody against "total"
p53 (CM5) was used on Western blot analysis to deter-
mine total protein levels in AL1 cells exposed to UV and
to MNNG and showed no increase in expression (Figure
7D–E). These results suggest that the axolotl p53 activity
is regulated by post-translational modifications in cells
exposed to UV and MNNG.
Discussion
The p53 sequences of lower vertebrates (amphibians and
fishes) that have been identified to date are quite diver-
gent from their mammalian counterparts. However, they
all conserve the basic domain organization described for
human p53. We investigated the axolotl p53 protein for
various reasons: First, this is a well characterized lower
vertebrate that has been used as a model organism for
over 100 years; second, axolotls display a remarkable
resistance to cancer [23,26,27,59,60]; and third axolotl is
long living, up to 25 years in captivity [18]. We are inter-
ested to determine to which extent p53 biology in axolotls
is linked to their remarkable ability to regenerate lost tis-
sues and their cancer resistance.BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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To address these questions, we tested whether p53 signal-
ing was required for limb regeneration. The administra-
tion of pifithrin-α blocked the process of limb
regeneration therefore providing evidence that p53 signal-
ing is required for regeneration in axolotls. These results
are consistent with the newly reported role of p53 require-
ment for regeneration of both axons in mice and imaginal
discs in drosophila [29,30]. Then, we cloned the axolotl
full-length p53 sequence and compared it to that of other
species, in particular human, and the naked mole rat
Spalax. We found an overall conservation of the p53 func-
tional domains as described for mammals. However, we
also found interesting amino acid changes, many of
which are unique to the axolotl (see Additional file 1).
First, the axolotl p53 was largely inactive at 37°C, which
can be explained by the presence of two changes in amino
acids (M160T & A189S) that have been shown to cause
the human protein to become temperature sensitive [50].
Also, the residue at position R174 in the human sequence
is changed to lysine in the axolotl. We noticed a similar
substitution in Spalax, Xenopus and the newt. In the
model of human tetrameric p53 bound to the DNA, R174
does not contact the DNA and it was proposed that it
interacts with R181 in an adjacent monomer [11]. The
neighboring R175 mediates interactions between the
loops that contact the DNA and may stabilize the core
structure of the DNA binding domain [61]. Mutation in
R175 to histidine makes DNA binding by p53 tempera-
ture sensitive [62]. Mice expressing R175H-p53 revealed
not only a dysfunctional protein but also gain of function
activities such as the ability to have a dominant negative
effect on wild type p53 and other p53 family members
such as p73 [63,64].
Another interesting change is the T155A which we found
is unique to the axolotl (Additional file 1). This position
is one of the most frequently mutated in human cancers.
However, the transactivation ability of the T155A protein
on several promoters is not significantly disabled by this
mutation and it is doubled on the Noxa promoter [48]. In
addition, phosphorylation of T155 by the COP9 signalo-
some targets p53 for degradation by the proteasome [65]
and disruption of the COP9 signalosome Csn2 subunit
results in a hyperactivation of p53 [66]. These results sug-
gest that the axolotl protein may be resistant to degrada-
tion allowing the protein to accumulate and therefore
could confer cancer resistance. In agreement with this
hypothesis, mice expressing extra-copies of p53 are also
cancer resistant [67].
We also studied the response of axolotl p53 to DNA dam-
aging agents such as UV light and an alkylating agent.
These results clearly indicate that p53 is activated follow-
ing UV irradiation in axolotl cells as reported in human
cells [68]. Also, our time course experiments showed an
increase in phospho-ser15 p53 in axolotl cells treated
with 10 μM of MNNG. Our data clearly confirms that p53
is activated in salamanders through similar mechanisms
Activation of Hdm2 and p21 promoters by human and axol- otl p53 in AL1 cells Figure 6
Activation of Hdm2 and p21 promoters by human 
and axolotl p53 in AL1 cells. (A-B) Dual-luciferase assays 
in AL1 cells with Hdm2 and p21 promoters at 25°C. All Luci-
ferase activities were significantly different from non-p53 
controls (at least p < 0.05, data not shown). Error bar ± 
s.e.m. human and axolotl p53 induced luciferase expression 
were significantly different with the Hdm2 promoter (p < 
0.01). Each assay was performed in triplicate at least 3 sepa-
rate times.
Activation of endogenous Hdm2 in H1299 cells by the axol- otl p53 protein Figure 5
Activation of endogenous Hdm2 in H1299 cells by 
the axolotl p53 protein. Expression of the human p53 tar-
get gene (Hdm2) 24 h post transfection in H1299 cells mock 
transfected and transfected with the axolotl p53 without and 
with pifithrin-α grown at 30°C. RT-PCRs were also per-
formed with the housekeeping gene glyceraldehyde phos-
phate dehydrogenase (Gapdh) to control for the amount of 
total RNA.BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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as described for mammalian cells under similar condi-
tions.
Multiple p53 codons are found mutated in human cancer
and many of them have been tested for transactivation,
induction of growth arrest or apoptosis. However, combi-
nations between different individual mutations have not
been systematically studied, mainly because their number
is obviously too large. The discovery of a natural p53 var-
iant containing a combination of mutations found in
human cancers is a rich source of structural data for fun-
damental studies about p53 and represents a window to
understand how certain selective pressures modify the
structure and the function of p53. For example, the p53
protein from Spalax was unable to regulate several pro-
moters of pro-apoptotic p53 targets and it was suggested
that this trait is an adaptation to hypoxic life [11]. It is
interesting to speculate that changes we have found in
axolotl are the result of selective pressures linked to the
life style of this animal, including its ability to regenerate
lost tissues.
In conclusion, our results present for the first time the p53
system in axolotls and open the way to study whether this
interesting protein is linked to the remarkable traits that
have evolved in these amphibians. Further characteriza-
tion of p53 in these animals may shed light into the evo-
lutionary adaptations of the p53 tumor suppressor
pathways to different physiological conditions and the
potential relationships with the aging/cancer process.
Detection of p53 protein in AL1 cells Figure 7
Detection of p53 protein in AL1 cells. (A & C) Western blot analysis of phospho-ser15 p53 in AL1 cells exposed to UV or 
treated with MNNG. (B) RT-PCR analysis of p53 target gene, Gadd45 (a p53 target gene cloned in axolotl [57, 58]), in control 
treated axolotl AL1 cells, cells exposed to UV (6h post-irradiation) and cells exposed to UV & treated with pifithrin-α. Both 
Gapdh and Ef1α were used as controls to demonstrate that the effects of UV and UV plus pifithrin-α were specific for Gadd45. 
(D-E) Western blot analysis of total p53 protein (CM5 antibody) on AL1 cells exposed to UV or treated with MNNG.BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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Methods
Animal procedures
Axolotls (Ambystoma mexicanum) were purchased from the
Axolotl colony (Ambystoma Genetic Stock Center, Lex-
ington KY). Larvae were maintained at 20–22°C in 40%
Holtfreter' solution. Animals (2.5–4 cm) were anaesthe-
tised in 0.1% MS222 solution for amputations through
both the upper (proximal) and lower (distal) part of the
forelimbs to induce regeneration. Pifithrin-α (Sigma-
Aldrich) was dissolved in 100% DMSO at a concentration
of 5 mM. Pifithrin-α was administered by adding directly
to the Holtfreter's solution to the desired concentration
(at least 9 animals were treated with 5 μM); treatment was
started at the time of amputation. The control animals
were treated with the same 100% DMSO that was used to
dissolve the pifithrin-α. All solutions were changed daily
until the controls had completely finished regenerating
their limbs (25 days post-amputation). Animals were
euthanized at the end of the experiment.
Cell lines
H1299 (p53-null lung cancer cell line) and IMR90
(human Caucasian fetal lung fibroblast) cell lines grown
in culture were maintained at a constant temperature of
37°C with 5% CO2 in Dulbecco's Modified Eagle Medium
(DMEM with 1× L-glutamine, 1× penicillin-streptomycin
and 10% Fetal Bovine Serum) (Gibco, Invitrogen,
Carlsbad, CA). Axolotl cells (AL1) were obtained from Dr.
S.V. Bryant and Dr. D.M. Gardiner at the University of Cal-
ifornia Irvine. AL1 cells grown in culture were maintained
at a constant temperature of 25°C without CO2 in Leibo-
vitz's L-15 medium (L-15 60.0% with 1× L-glutamine, 1×
antibiotic-antimycotic, 1× insulin-transferrin-selenium
and 5% Fetal Bovine Serum) (Gibco, Invitrogen,
Carlsbad, CA).
Cloning and sequence analysis of axolotl p53 cDNA
Partial axolotl p53 cDNA sequences were cloned by RT-
PCR using degenerate primers [partial axolotl p53 forward
(DFPROP53)] 5'-GG(A/C/G/T)(C/T)T(A/C/G/T)GC(A/
C/G/T)AA(A/G)ACITG(C/T)CC-3' and [partial axolotl
p53 reverse (DRPROP53)] 5'-G(G/T)(A/G)TTCAT(G/
T)CC(G/T)CCCAT(A/G)CA-3'. To obtain the full length
p53 gene, we performed a screening of Salamander Larvae
Lambda cDNA Library (Stratagene, La Jolla, CA), with the
partial p53 cDNA sequence obtained. The open reading
frame of the p53 protein was identified after sequencing
several cDNA isolates from the library (4 different iso-
lates). Two primers with a restriction site on each side
(5'Xho1 and 3'BstX1) were made to facilitate the cloning
of full length axolotl p53 in the FG12/CMV vector (M.
Soengas, Ann Arbor). Full length p53 cDNA was subse-
quently amplified by PCR using [axolotl p53 forward
XHO (APFXHO)] 5'-GAGCCTCGAGGAATCGGAAAC-
CACCATGGA-3' and [axolotl p53 reverse BSTX (APRB-
STX)] 5'-
GCGCCCATCTTTATGGGAATACAGGCACCATTGCAG-3'
primers. PCR reactions were performed using Taq DNA
polymerase (Invitrogen, USA). All PCR products were
purified by Rapid gel extraction (Gibco), cloned into the
pCR 4-TOPO vector (Invitrogen, USA) and sequenced by
the McGill Genome Sequencing Centre with M13R and
M13F primers. Resulting sequences were assembled using
SeqManII (DNASTAR Inc., USA). All sequences were ana-
lysed on the NCBI BLAST database (axolotl p53 GEN-
BANK sequence accession number: DQ848588).
Transfection of human cells and dual luciferase reporter 
assay
H1299 cells were transfected at a confluence of 90% in 6
wells plates, with 2.5 μg of the firefly luciferase reporter
plasmid (p21 waf-1-luc or Hdm2 in pGL3 vector;
Promega), 0.5 μg of a plasmid expressing either human
p53 (pLPChp53 containing the CMV promoter), axolotl
p53 (FG12/CMV-Ap53) or FG12/CMV as control. A plas-
mid expressing Renilla luciferase under the β-globin pro-
moter was co-transfected (0.5 μg) to normalize the results
of the assays. Transfection was done with lipofectamine
2000 (Invitrogen, U.S.A.) according to the manufacturer's
instructions. H1299 cells were incubated at different tem-
peratures (37°C, 30°C or 25°C) following transfection.
24 hours after transfection H1299 cells were rinsed with
Hank's buffer and harvested with trypsin (Invitrogen,
CA). They were resuspended in 200 μl of fresh passive
lysis buffer (Promega), vortexed, frozen in liquid nitrogen
and stored at -80°C. Luciferase assay was performed fol-
lowing the standard protocol for the Dual-Luciferase®
Reporter Assays System (Promega, Madison, WI). The
assays were read on a Fusion α-FP luminometer (Packard
Instrument Company, Inc., Meriden, CT). For the experi-
ments combining the human and axolotl p53 we used 0.5
μg of plasmids expressing human and axolotl p53 (or
FG12/CMV for control), 2.5 μg of the firefly luciferase
reporter plasmid (Hdm2 in pGL3 vector) and 0.5 μg of
plasmid expressing Renilla luciferase under the β-globin
promoter.
Electroporation of axolotl cells and dual luciferase 
reporter assay
An electroporation protocol was developed to transfect
the AL1 cells for the Dual Luciferase® Reporter Assay. Cells
were co-transfected with 5 μg of the firefly luciferase
reporter plasmid (p21 waf-1-luc or Hdm2 in pGL3 vector;
Promega) and with 1 μg of a plasmid expressing either
human p53 (pLPChp53), axolotl p53 (FG12/CMV-Ap53)
or empty FG12/CMV as control. The same plasmid
expressing Renilla luciferase under the β-globin promoter
(1 μg) was used to normalize the results of the assays. The
transfection was performed using a Gene-Pulser Xcell
Eukaryotic System (Bio-Rad) generating a single electros-BMC Evolutionary Biology 2007, 7:180 http://www.biomedcentral.com/1471-2148/7/180
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quare pulse of 250 volts during 35 milliseconds, in a 4
mm cuvette (VWR) containing approximately 60 000 AL1
cells resuspended in 100 μl of ice cold 0.7× PBS. 48 hours
after electroporation, axolotl cells were rinsed twice with
0.7× PBS, lysed with 250 μl of fresh 1× passive lysis buffer
and placed on a shaker with gentle agitation for 20 min-
utes. The cells were collected, frozen in liquid nitrogen
and stored at -80°C. Luciferase assays were performed as
described above.
RT-PCR
Total RNA was extracted from either H1299 cells of axol-
otl AL1 cells using Trizol reagent (Invitrogen, Carlsbad,
CA). Reverse transcription reactions were done at 50°C
using Superscript II reverse transcriptase (Invitrogen). The
cDNA fragments encoding for the human Hdm2 (Gen-
bank # CO783557) and the axolotl Gadd45 (Genbank #
NM_002392) were amplified by RT-PCR from total RNA
with the following primers: Hdm2 forward CAGCTTCG-
GAACAAGAGACC, reverse GAAGCCAATTCTCAC-
GAAGG; Gadd45 forward CGTGCACCTTACTTGGGACT,
reverse ATGTCATTGTCGCAGCAAAA. Gapdh and EF1-α
were used as control PCR using the following primers:
human Gapdh forward ACCACAGTCCATGCCATCAC,
reverse TCCACCACCCTGTTGCTGTA and for the axolotl
EF1-α forward AACATCGTGGTCATCGGCCAT, reverse
GGAGGTGCCAGTGATCATGTT, and Gapdh forward
GACAAGGCATCTGCTCACCT and reverse ATGTTCT-
GGTTGGCACCTCT. RT-PCR reactions were performed on
at least 3 separate RNA preparations.
Colony assays
The H1299 cells used for the colony assays were trans-
fected with lipofectamine 2000 according to the manufac-
turer's instructions. The pLPChp53, the FG12/CMV-Ap53
or the FG12/CMV empty vectors (12 μg) were co-trans-
fected with a puromycin resistant vector (12 μg, pBabe-
lacZ) for colony selection. The colony assay was per-
formed 1 week post-transfection at 37, 30 and 25°C in
DMEM. The selection was made with 1 μg/ml of puromy-
cin (Sigma-Aldrich, St-Louis, MO). Colonies were colored
with crystal violet (Sigma-Aldrich, St-Louis, MO).
Immunoblots
AL1 cells used in western blotting were exposed to UV
(100 j/m2) using a XL-1000 UV Crosslinker (Spectronics
Corporation, NY, USA). AL1 cells were harvested 6, 12
and 24 hours post-irradiation. Total proteins of axolotl
cells were extracted by sonication in sodium dodecyl sul-
phate (SDS) sample buffer. AL1 cells used in western blot-
ting were also treated with MNNG (1-methyl-3-nitro-1-
nitrosoguanidine, Sigma-Aldrich, St-Louis, MO), during
1, 3, 6, 12 and 24 hours, then harvested post-treatment.
Total proteins where prepared by sonication as men-
tioned above. The protein quantification was done using
the Bradford technique [69]. 40 μg of cell proteins were
denatured by boiling and loaded on 10% polyacrylamide-
SDS gels following the Laemmli method [70]. Proteins
were then transferred onto polyvinylidene difluoride
membranes (Immobilon-P, Millipore, Bedford, MA).
Anti-Pp53 ser15 (#9284, Cell Signaling technology, MA)
and Anti-p53 CM5 (NCL-p53-CM5p, Novo Castra labora-
tory, UK) rabbit affinity isolated antibodies were used to
detect axolotl p53. Immunodetection of primary antibod-
ies was visualized using the ECL Western blotting kit
(Amersham Pharmacia, Amersham, United Kingdom) or
Lumi-light Western Blotting Substrate (Roche) following
manufacturer's guidelines. Anti-α-tubulin (Tubulin-α Ab-
2 clone DM1A, Neo Marker distributed by Medicorp, Qc)
was used as loading control. IMR90 cells were used as a
positive control for normal expression of p53 protein.
Sequence handling and phylogenetic analyses
All protein sequences were retrieved from NCBI GenBank
after identification by a BLASTP search, with the salaman-
der p53 protein sequence as query (except for the newt
(Notophthalmus viridescens) p53 sequence which was the
generous gift from Dr J. Brockes University College Lon-
don). Clustal V was used to create the original alignment
that was manually further optimised and redundant
sequences were discarded using the edit option of the
MUST package. G-blocks was used to eliminate variable
regions of the alignment. The maximum likelihood phyl-
ogenetic tree was inferred by the program Treefinder using
the WAG matrix of amino acid replacement under the
assumption of four discrete gamma-distributed rates. The
statistical robustness of internal nodes was estimated by
the bootstrap method, based on 100 replicates using the
same program and model as before. The consensus tree of
these 100 bootstrap replicates was generated with the con-
sense option of the PHYLIP package. The bootstrap sup-
port values given in percent are indicated on the
corresponding nodes.
Statistics
Statistics for the Dual Luciferase Reporter Assay System
were performed with SysStat® (Systat Software Inc, USA).
One-sample t-test was used to calculate the p-value
between control and experimental assays. A two-sample t-
test was used to calculate the p-value between experimen-
tal assays in same condition. Graphics were made with
Origin® (OriginLab Corporation, USA).
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Analysis of the changes in aa of the axolotl p53 protein compared to the 
p53 proteins of multiple vertebrates. This is a supplement to table-2 where 
we show that 38 aa positions known to be mutated in p53 from human 
cancers are changed in the axolotl as well. Most of these positions are also 
changed in the p53 from other vertebrates, however we highlighted in yel-
low positions that are only changed in the axolotl at aa A189S, D208N 
& G262E. We also highlighted in blue the positions where only the axolotl 
showed a non-conservative aa change (T155A, D186N, L188D, D207M 
& D228G). The data presented in this figure was generated by the pair-
wise alignment of the human p53 protein sequence with the protein 
sequence of each organism. The position number refers to the aa position 
in the human p53 protein. Gaps in aa sequence alignment are represented 
by a star (*).
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